You just read:

DelMar Pharmaceuticals Achieves Two-Thirds Enrollment for Phase 2 Clinical Trial of VAL-083 As First-Line Treatment in Newly-Diagnosed MGMT-Unmethylated Glioblastoma MultiForme (GBM)

News provided by

DelMar Pharmaceuticals, Inc.

Jul 31, 2019, 08:00 ET